bis-(triazoloacridinones), 11) bis-(anthracyclines), 12, 13) bis-(acridine-4-carboxamides), 14) bis-(phenazine-1-carboxamides) 15, 16) and bis-(indeno [1,2-b] quinoline-6-carboxamides). 17) A comparative study of a variety of bis analogues with their monomeric counterparts has revealed that there are variable but significant gains in potency for the dimeric species. 18) Due to interesting biological activities and unique chemical structures, bis analogues of various naturally occurring alkaloids serve as lead compounds for discovery of new drugs. 19) Dimeric analogues of a number of classes of chromophores joined by various cyclic and acyclic linkers are also of current interest as potential antispasmodic agents. 20) Natural bis-(isoquinoline) alkaloids have emerged as an important structural class based upon their high degree of biological activity. 21) A typical example is tetrandrine, 22) a potent antispasmodic agent. Papaverine, a benzylisoquinoline alkaloid, is a well known smooth muscle relaxant and a vasodilator. 23, 24) Considering these factors and in continuation to our earlier efforts 25, 26) of finding a potent antispasmodic agent, we envisaged that dimers of papaverine with suitable linkers at nitrogen can turn out to be more potent antispasmodic agents in comparison to papaverine.
Herein, we report the synthesis and antispasmodic activity of a series of bis-(tetrahydropapaverine) analogues with urea and acetyl linkers.
Results and Discussion
For the purpose of this study, numerous bis-(tetrahydropapverine) analogues 6-13 were readily prepared by direct reaction of tetrahydropapaverine (5) (2 molar equivalent) with the corresponding (i) substituted bis-(isocyanates) and (ii) substituted bis-(isothiocyanates) in acetonitrile (Chart 1). In a typical reaction amide 3 required for the synthesis of tetrahydropapaverine (5) was prepared by the condensation of homoveratryl amine (1) and homoveratric acid (2) in xylene with azeotropic removal of water. Cyclization of amide 3 to 3,4-dihydroisoquinoline (4) was achieved in Bischler-Napierlaski fashion, in refluxing toluene with phosphorous oxychloride. Reduction of 3,4-dihydroisoquinoline with sodium borohydride in methanol resulted in the formation of tetrahydropapaverine 5 (Chart 1).
26) Products 6-13 were obtained in 80-85% yield and were purified by column chromatography.
Reaction of tetrahydropapaverine (5) with chloroacetylchloride and triethylamine in dichloromethane lead to the formation of N-(chloroacetyl)tetrahydropapaverine (14) . The reaction of tetrahydropapaverine (5) and N-(chloroacetyl)tetrahydropapaverine (14) in acetone in the presence of potassium carbonate and tetrabutylammonium iodide at room temperature yielded 15 (Chart 2). The direct reaction of N-(chloroacetyl)tetrahydropapaverine (14) (2 molar equivalent) with piperazine or cis-2,6-dimethylpiperazine or homopiperazine (1 molar equivalent) in acetone in the presence of potassium carbonate and tetrabutylammonium iodide yielded 16-18 respectively (Chart 3). Products 16-18 were purified by column chromatography eluting with ethylacetate and hexane and obtained in 73-76% yields.
Tetrahydropapaverine efficiently displaced one of the imidazole rings of carbonyldiimidazole 26) to give tetrahydropapaverine carbamoyl imidazole 19 on refluxing it with carbonyldiimidazole (CDI) in tetrahyrofuran (THF) for 24 h. The reaction of methyl iodide with carbamoyl imidazole 19 (4 molar equivalents) in acetonitrile for one day at room temperature produced the imidazolium salt quantitatively. This imidazolium salt required no additional purification for final conversion to ureas. Addition of tetrahydropapaverine to a solution of imidazolium salt in dichloromethane with triethylamine at room temperature afforded tetra substituted urea derivative 21 (Chart 4). It was purified by column chromatography and obtained in 79% yield. The activation of the leaving imidazole ring was found to be necessary for the formation of desired ureas since the carbamoyl imidazoles were unreactive towards tetrahydropapaverine even under refluxing conditions for prolonged periods. Addition of triethylamine (1 molar equivalent) resulted in improved yields of ureas.
The reaction of imidazolium salt 20 (2 molar equivalent) with piperazine or cis-2,6-dimethylpiperazine or homopiperazine (1 molar equivalent) in dichloromethane and triethylamine (Chart 5) afforded compounds 22-24 respectively. These compounds were purified by column chromatography and obtained in 75-80% yield.
Antispasmodic activity studies of compounds 6-13, 15-18, and 21-24 were performed on guinea pig ileum. Acetylcholine (10 Ϫ3 M) was used to induce sustained contraction in guinea pig ileum. When the contraction response to acetylcholine reached a steady level, papaverine was added cumulatively. Papaverine inhibited the acetylcholine induced contraction in a concentration dependent manner. Similarly, acetylcholine induced contraction inhibition by tetrahydropapaverine derivatives 6-13, 15-18, and 21-24 were studied. Dose-response curves were obtained for papaverine and all these derivatives. The results revealed that most of the test compounds 6-13, 15-18, and 21-24 more potently inhibited the acetylcholine induced contractions than papaverine. Table 1 summarizes the concentration of papaverine and test compounds producing 50% relaxation (IC 50 ) of acetylcholine induced contraction for compounds 6-13 and (6) (7) (8) (9) (10) (11) (12) (13) . Second category has piperazinyl, substituted piperazinyl ring placed between two acetyl groups, as linkers (15) (16) (17) (18) . Third category consists of piperazinyl, substituted piperazinyl ring placed between two carbamoyl groups, as linkers (21) (22) (23) (24) . Among the three types of linkers, the compounds with third category of linkers (21) (22) (23) (24) were found to be most potent. The corresponding compounds with CH 2 spacers (15-18), exhibited a decrease in antispasmodic activity. The compounds with trisubstituted urea spacers (6-13) were found to be least active among the bis-(tetrahydropapaverine) derivatives reported.
The bis-(tetrahydropapaverine) derivatives with trisubstituted urea spacers 6-13 exhibited antispasmodic activities not significantly different from papaverine. Compound 6, with a benzene ring as a spacer, introduced between the two amide groups, gave IC 50 value of 6.17 mM. Its thio analogue 9 exhibited a small decrease in antispasmodic activity. Substitution of a cyclohexane ring 8 in place of benzene ring decreased the antispasmodic activity (IC 50 : 9.31 mM). Compound 10 with an aliphatic chain as the spacer between the two thiomide groups exhibited IC 50 value further lower as compared to compound 8. Compounds 11 and 12 having methyl group substituted in benzene ring were not as good antispasmodic agents as papaverine. They exhibited IC 50 values similar to that exhibited by compounds 8 and 10. Substitution of a chloro group in addition to a methyl group in the benzene ring (13) Among the tetra substituted urea derivatives 21-24, the IC 50 value of 21 was found to be 0.42 mM. Addition of a piperazine spacer between the two carbamoyl groups further increased the antispasmodic activity (IC 50 : 0.31 mM). Methyl substitution (23) on the piperazine ring at positions 2 and 6, lead to a fall in the activity (IC 50 : 0.75 mM). Substitution of homopiperazine ring (24) in place of piperazine ring slightly increased the activity (IC 50 : 70 mM).
Compound 10 is the least potent and compound 22 is the most active bis-(tetrahydropapaverine) analogue of the series.
Conclusion
N-Substituted bis-(tetrahydropapaverine) derivatives showed better antispasmodic activity in comparison with papaverine in guinea pigs in preliminary screenings. Compounds with tetra substituted urea linkers were found to be more active than compounds with trisubstituted urea linkers and compounds with acetyl linkers. Compound 22 was found to be the most potent compound among the series. However, contrary to our predictions, none of the bis analogues were able to beat the best compound of our previously reported 26) piperazinyl based tetra substituted urea derivative of papaverine.
Experimental
Melting points are recorded in open capillary tubes on Buchi melting point B-540 instrument and are uncorrected. Solvent system used throughout the experimental work for running TLC plates was ethylacetate-hexane. The 1 H-NMR spectra were recorded in CDCl 3 as solvent (using TMS as internal standard) on a Bruker Avance Spectrospin 300 instrument at 300 MHz. Mass spectra were run on a Perkin Elmer LCMS API-2000 mass spectrometer. IR spectra were recorded using KBr discs on a Shimadzu FTIR-8300 spectrophotometer. Elemental analysis was carried out on Heraeus Rapid CHN analyser.
N,N-[1,4-Benzene-{diyl-bis-(iminocarbonyl)}-bis-{1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline}] (6) A solution of 1,4-phenylenediisocyanate (0.192 g, 1.2 mmol) in dry acetonitrile (5 ml) was added slowly to a solution of tetrahydropapaverine 5 (0.686 g, 2 mmol) in dry acetonitrile (5 ml). The mixture was stirred at room temperature for 2 h. After the completion (TLC) of the reaction, evaporated off the solvent, diluted the residue with water (25 ml) and extracted with ethylacetate (3ϫ25 ml). The collective organic portion was washed with brine and dried (Na 2 SO 4 ). It was concentrated under reduced pressure and the residue was chromatographed on silica gel using ethylacetate-hexane as eluent. A final recrystallization from ethylacetate-hexane (15 : 85) afforded pure 6 as a viscous solid (0.685 g, 81%). 
N,N-[1,4-Benzene-{diyl-bis-(iminothiocarbonyl)}-bis-{1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline}]
(9) Synthesized, from 5 and 1,4-phenylenediisothiocyanate, in a manner similar to that described for 6. The product was obtained as a white solid (85%) mp 126-128°C. 
N,N-[1,4-Butane-{diyl-bis-(iminothiocarbonyl)}-bis-{1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline}] (10)
Synthesized, from 5 and 1,4-butanediisothiocyanate, in a manner similar to that described for 6. The product was obtained as a white solid (83%) mp 56-58°C. 
N,N-[1,3-Benzene-{diyl-bis-(iminocarbonyl)-2-methyl}-bis-{1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline}] (11)
Synthesized, from 5 and 2-methyl-m-phenylenediisocyanate, in a manner similar to that described for 6. The product was obtained as a white solid (81%) mp 171-172°C. {1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-1,2,3 ,4-tetrahydroisoquinoline}] (13) Synthesized, from 5 and 4-chloro-6-methyl-m-phenylenediisocyanate, in a manner similar to that described for 51. The product was obtained as a viscous solid (84% N,N-Bis-[2-acetyl-1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline] (15) To a solution of 1-(3,4-dimethoxybenzyl)-2-chloroacetyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline (14) (0.85 g, 2 mmol) and tetrahydropapaverine (5) (0.68 g, 2 mmol) in acetone (10 ml) was added activated K 2 CO 3 (1 g, 7.2 mmol) and tetrabutylammonium iodide (0.18 g, 0.5 mmol). The mixture was stirred for 12 h at room temperature. After the completion (TLC) of reaction, acetone was evaporated and diluted the reaction mixture with water (25 ml) and extracted with ethylacetate (3ϫ25 ml). The collective organic portion was washed with brine and dried over Na 2 SO 4 . It was concentrated under reduced pressure and the residue was chromatographed on silica gel using ethylacetate-hexane as eluent to obtain pure 47 as a white solid (1.08 g, 75%) mp 74-75°C. 45 (4H, m), 3.04 (4H, m), 3.39 (4H, m), 3.50 (2H,  s), 3.74 (2ϫ3H, s), 3.81 (2ϫ3H, s), 3.87 (4ϫ3H, s) (14) (0.85 g, 2 mmol) and piperazine (0.086 g, 1 mmol) in acetone (10 ml) was added activated K 2 CO 3 (1 g, 7.2 mmol) and tetrabutylammonium iodide (0.18 g, 0.5 mmol). The mixture was stirred for 12 h at room temperature. After the completion (tlc) of reaction, acetone was evaporated and diluted the reaction mixture with water (25 ml) and extracted with ethylacetate (3ϫ25 ml). The collective organic portion was washed with brine and dried over Na 2 SO 4 . It was concentrated under reduced pressure and the residue was chromatographed on silica gel using ethylacetate-hexane as eluent to obtain pure 16 as a pale yellow solid (0.64 g, 76%) mp 80-82°C. ) and tetrahydropapaverine (0.68 g, 2 mmol) in anhydrous dichloromethane was added triethylamine (0.27 ml, 2.0 mmol). The mixture was stirred at room temperature for 12 h, then washed with 1.0 M HCl (10 ml), the organic layer dried over anhydrous Na 2 SO 4 , filtered and concentrated under vacuum to yield the required tetra substituted urea as an oil which was column chromatographed (ethylacetate-hexane) to obtain pure 21 as a white solid (1.12 g, 79%) mp 68-69°C. The mixture was stirred at room temperature for 12 h, then washed with 1.0 M HCl (10 ml), the organic layer dried over anhydrous Na 2 SO 4 , filtered and concentrated under vacuum to yield the required tetra substituted urea as an oil which was column chromatographed (ethylacetate-hexane) to obtain pure 22 as a light yellow solid (0.61 g, 75%) mp 73-74°C. 73 (8H, m), 2.88 (4H, m), 2.92 (4H, m) Pharmacological Methods Antispasmodic activity: isolated guinea pig ileum Guinea pigs of both sexes (300-500 g) were sacrificed by cervical dislocation and exsanguinated. The abdomen was opened and the terminal ileum carefully dissected, repeatedly washed and the connective tissue removed. Intestinal segments of 1.0 to 1.5 cm length were set up under 1 g resting tension in a 10 ml organ bath with Tyrode's solution: (mM: NaCl 137, KCl 2.7, CaCl 2 1.8, MgCl 2 1.05, NaHCO 3 11.9, NaH 2 PO 4 0.42, glucose 5.6). The bath temperature was maintained at 37°C and aerated with compressed air. Tension changes in the tissues were monitored using force displacement transducer amplifier connected to physiograph (Polyrite, Recorders and Medicare System).
After 30 min of equilibration period, concentration-response curves to the cumulative addition of acetylcholine (ACh) (0.1 nM-0.1 mM) were constructed. After constant responses had been obtained, concentration-response was repeated in the presence of increasing concentrations of the standard antagonist papaverine (0.1-20 mM). After a further control experiment (concentration-response curve of ACh) the test compounds 6-13, 15-18 and 21-24 were measured. All substances were incubated 3 min prior to the cumulative addition of ACh; after each experiment all substances were carefully washed out. For each test substance a new ileum preparation was used. Test compounds were dissolved in 46% EtOH to yield solutions (0.1-20 mM). The antispasmodic activity was assessed as a percent reduction over the initial value. The IC 50 values (concentration required to inhibit the 100% [E max ] Ach response to 50%) were obtained from individual experiments with 3 to 5 different concentrations of test compounds. As EtOH in the concentration used also inhibits ACh-induced contractions the antispasmodic activity of EtOH was measured and subtracted from the values obtained with test compounds.
